Payment overview · 2025
General Payments
$190.69
10 reported records · 7 companies
Healthcare provider profile · identity verified
Nicolas Alonso, DO
Allopathic & Osteopathic Physicians|Internal Medicine · CONROE, TX · NPI 1043666233
Verified facts
What the public records show
CMS Open Payments records show Nicolas Alonso, DO received $190.69 in general payments during 2025 across 10 reported records.
Astellas Pharma US Inc accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.14 | 23.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.04 | 17.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.90 | 17.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.06 | 12.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.18 | 11.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.06 | 10.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.31 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $190.69 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.14 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 113 |
| Losartan Potassium | Losartan Potassium | 386 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 379 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 72 |
| Lisinopril | Lisinopril | 247 | 76 |
| Metformin Hcl | Metformin Hcl | 231 | 74 |
| Gabapentin | Gabapentin | 187 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 63 |
| Azithromycin | Azithromycin | 170 | 129 |
| Furosemide | Furosemide | 170 | 65 |
| Carvedilol | Carvedilol | 150 | 47 |
| Omeprazole | Omeprazole | 145 | 48 |
| Meloxicam | Meloxicam | 140 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 46 |
| Methylprednisolone | Methylprednisolone | 134 | 101 |
| Montelukast Sodium | Montelukast Sodium | 131 | 48 |
| Simvastatin | Simvastatin | 128 | 40 |
| Alendronate Sodium | Alendronate Sodium | 120 | 38 |
| Ozempic | Semaglutide | 119 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 36 |
| Trazodone Hcl | Trazodone Hcl | 101 | 38 |
| Famotidine | Famotidine | 97 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 29 |
| Cefdinir | Cefdinir | 94 | 73 |
| Celecoxib | Celecoxib | 93 | 27 |
| Tramadol Hcl | Tramadol Hcl | 93 | 33 |
| Eliquis | Apixaban | 92 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 31 |
| Mounjaro | Tirzepatide | 90 | 19 |
| Sertraline Hcl | Sertraline Hcl | 89 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 31 |
| Allopurinol | Allopurinol | 80 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 25 |
| Ezetimibe | Ezetimibe | 61 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 20 |
| Finasteride | Finasteride | 60 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 17 |
| Atenolol | Atenolol | 59 | 17 |
| Alprazolam | Alprazolam | 54 | 14 |
| Glimepiride | Glimepiride | 54 | 18 |
| Potassium Chloride | Potassium Chloride | 54 | 15 |
| Buspirone Hcl | Buspirone Hcl | 53 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 36 |
| Clonazepam | Clonazepam | 50 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 31 |
| Prednisone | Prednisone | 48 | 14 |
| Spironolactone | Spironolactone | 48 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 14 |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | 15 |
| Mirtazapine | Mirtazapine | 39 | 15 |
| Valsartan | Valsartan | 38 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 12 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 18 |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Mupirocin | Mupirocin | 28 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Nystatin | Nystatin | 27 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 19 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 21 |
| Levofloxacin | Levofloxacin | 23 | 16 |
| Fluconazole | Fluconazole | 22 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Euthyrox | Levothyroxine Sodium | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 19 |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 15 |
| Topiramate | Topiramate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 11 | suppressed |
| Tivicay | Dolutegravir Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $190.69 · 10 records | Astellas Pharma US Inc | Dexcom G6 Transmitter, ELIQUIS, FARXIGA, Fluad, Flucelvax, NURTEC ODT, SYNTHROID, VRAYLAR, Veozah, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error